Novel insights into the role of urotensin II in cardiovascular disease.

Urotensin II (UII) is a vasoactive peptide that interacts with a specific receptor called the UT receptor. UII has been implicated in cardiovascular regulation, with promising therapeutic applications based on UT receptor antagonism. The endogenous ligands of the UT receptor: UII and urotensin-related peptide (URP), differentially bind and activate this receptor. Also, the receptor localization is not restricted to the plasma membrane, possibly inducing different physiological responses that could support its inconsistent, but potent, vasoactive activity. These properties could explain the disappointing outcomes in clinical studies, in contrast to the positive preclinical results regarding heart failure, pulmonary hypertension, atherosclerosis and diabetes mellitus. These aspects should be considered in future investigations to a better comprehension of the role of UII as a potential therapeutic target.

• Publication year

  2019

• Venue

  Drug Discovery Today

• Publication date

  2019-08-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.drudis.2019.08.005PMID 31430542
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Novel and Highly Potent Urotensin II Receptor Antagonist Inhibits Urotensin II–Induced Pressure Response in Mice

  2019cited by this paper
• Urotensin-#receptor antagonist SB-706375 protected isolated rat heart from ischaemia–reperfusion injury by attenuating myocardial necrosis via RhoA/ROCK/RIP3 signalling pathway

  2019cited by this paper
• Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl4-induced cirrhotic rats

  2019cited by this paper
• Discovery of New Allosteric Modulators of the Urotensinergic System through Substitution of the Urotensin II-Related Peptide (URP) Phenylalanine Residue.

  2018cited by this paper
• The role of human urotensin-II in patients with hypertrophic cardiomyopathy

  2018cited by this paper
• Silymarin ameliorates expression of urotensin II (U-II) and its receptor (UTR) and attenuates toxic oxidative stress in the heart of rats with type 2 diabetes.

  2018cited by this paper
• Urantide improves the structure and function of right ventricle as determined by echocardiography in monocrotaline-induced pulmonary hypertension rat model

  2018cited by this paper
• Urotensin-II gene rs228648 polymorphism associated with the risk of diabetes mellitus

  2018cited by this paper
• A novel urotensin II receptor antagonist, KR‐36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure

  2017cited by this paper
• Role of PKA in the process of neonatal cardiomyocyte hypertrophy induced by urotensin II.

  2017cited by this paper
• Expressions of irisin and urotensin II and their relationships with blood pressure in patients with preeclampsia

  2017cited by this paper
• A Novel Urotensin II Receptor Antagonist, KR-36996 Inhibits Smooth Muscle Proliferation through ERK/ROS Pathway

  2017cited by this paper
• Design, Synthesis, and Biological Assessment of Biased Allosteric Modulation of the Urotensin II Receptor Using Achiral 1,3,4-Benzotriazepin-2-one Turn Mimics.

  2017cited by this paper
• The Urotensin II System and Carotid Atherosclerosis: A Role in Vascular Calcification

  2016cited by this paper
• Urotensin II induction of neonatal cardiomyocyte hypertrophy involves the CaMKII/PLN/SERCA 2a signaling pathway.

  2016cited by this paper
• The value of urotensin II in patients with left-sided rheumatic valvular regurgitation

  2016cited by this paper
• Genetic polymorphisms of UTS2 rs2890565 Ser89Asn in cardiac hypertrophy in Chinese Han population

  2016cited by this paper
• Urotensin-ⅡReceptor Antagonist SB-710411 Protects Rat Heart against Ischemia-Reperfusion Injury via RhoA/ROCK Pathway

  2016cited by this paper
• A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.

  2016cited by this paper
• Blockade of Urotensin II Receptor Prevents Vascular Dysfunction

  2016cited by this paper
• An investigation into the origin of the biased agonism associated with the urotensin II receptor activation

  2015cited by this paper
• The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy

  2015cited by this paper
• An investigation into the expression and mechanism of action of urotensin II in chronic pressure-overloaded rat hearts

  2015cited by this paper
• Association between essential hypertension and three vasoactive peptides, urotensin II, endothelin and adrenomedullin

  2015cited by this paper
• International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function

  2015cited by this paper
• Palosuran Treatment Effective as Bosentan in the Treatment Model of Pulmonary Arterial Hypertension

  2014cited by this paper
• Biased signaling regulates the pleiotropic effects of the urotensin II receptor to modulate its cellular behaviors

  2014cited by this paper
• Discovery of new antagonists aimed at discriminating UII and URP‐mediated biological activities: insight into UII and URP receptor activation

  2013cited by this paper
• Development and pharmacological characterization of conformationally constrained urotensin II-related peptide agonists.

  2013cited by this paper
• The differential extraction and immunoluminometric assay of Urotensin II and Urotensin-related peptide in heart failure.

  2013cited by this paper
• Association between Human Urotensin II and Essential Hypertension—A 1:1 Matched Case-Control Study

  2013cited by this paper
• The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats

  2013cited by this paper
• Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes

  2013cited by this paper
• Biochemical and pharmacological characterization of nuclear urotensin‐II binding sites in rat heart

  2012cited by this paper
• Urotensin Inhibition with Palosuran Could Be a Promising Alternative in Pulmonary Arterial Hypertension

  2012cited by this paper
• Genetic and Pharmacological Manipulation of Urotensin II Ameliorate the Metabolic and Atherosclerosis Sequalae in Mice

  2012cited by this paper
• Association Between Thr21Met and Ser89Asn Polymorphisms of the Urotensin-II (UTS2) Gene, Diabetes Mellitus, and Diabetic Retinopathy

  2012cited by this paper
• Presence of urotensin-II receptors at the cell nucleus: specific tissue distribution and hypoxia-induced modulation.

  2012cited by this paper
• Potent cardiovascular effects of homologous urotensin II (UII)-related peptide and UII in unanesthetized eels after peripheral and central injections.

  2011cited by this paper
• Urantide alleviates monocrotaline induced pulmonary arterial hypertension in Wistar rats.

  2011cited by this paper
• The pro-angiogenic activity of urotensin-II on human vascular endothelial cells involves ERK1/2 and PI3K signaling pathways.

  2010cited by this paper
• Urotensin II, from fish to human

  2010cited by this paper
• Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy

  2010cited by this paper
• The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation.

  2010cited by this paper
• Urotensin II receptor antagonist attenuates monocrotaline-induced cardiac hypertrophy in rats.

  2010cited by this paper
• Prediction of the Three‐Dimensional Structure for the Rat Urotensin II Receptor, and Comparison of the Antagonist Binding Sites and Binding Selectivity between Human and Rat Receptors from Atomistic Simulations

  2010cited by this paper
• Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3beta signaling pathway.

  2010cited by this paper
• Characterization of the insulinostatic effect of urotensin II: a study in the perfused rat pancreas.

  2009cited by this paper
• Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus.

  2009cited by this paper
• Urotensin II-induced increase in myocardial distensibility is modulated by angiotensin II and endothelin-1.

  2009cited by this paper
• Central and peripheral cardiovascular, ventilatory, and motor effects of trout urotensin-II in the trout.

  2008cited by this paper
• Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5.

  2008cited by this paper
• Structure-activity relationships of urotensin II and URP.

  2008cited by this paper
• Human urotensin II induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells: an emerging role for urotensin II in cardiovascular disease

  2008cited by this paper
• Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues

  2008cited by this paper
• Direct Inotropic Effects of Exogenous and Endogenous Urotensin-II: Divergent Actions in Failing and Nonfailing Human Myocardium

  2008cited by this paper
• Urotensin II: A New Pharmacologic Target in the Treatment of Cardiovascular Disease

  2008cited by this paper
• Role of urotensin II and its receptor in health and disease

  2007cited by this paper
• Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling

  2007cited by this paper
• Urotensin II is a New Chemotactic Factor for UT Receptor-Expressing Monocytes1

  2007cited by this paper
• Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats

  2007cited by this paper
• Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers.

  2006cited by this paper
• Human Urotensin-II Potentiates the Mitogenic Effect of Mildly Oxidized Low-Density Lipoprotein on Vascular Smooth Muscle Cells: Comparison with Other Vasoactive Agents and Hydrogen Peroxide

  2006cited by this paper
• Comparative genomics provides evidence for close evolutionary relationships between the urotensin II and somatostatin gene families

  2006cited by this paper
• The role of urotensin II in cardiovascular and renal physiology and diseases

  2006cited by this paper
• Cardiovascular effects of native and non-native urotensin II and urotensin II-related peptide on rat and salmon hearts.

  2006cited by this paper
• Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease.

  2006cited by this paper
• Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients

  2006cited by this paper
• The Urotensin-II Receptor Antagonist Palosuran Improves Pancreatic and Renal Function in Diabetic Rats

  2006cited by this paper
• The peptidic urotensin‐II receptor ligand GSK248451 possesses less intrinsic activity than the low‐efficacy partial agonists SB‐710411 and urantide in native mammalian tissues and recombinant cell systems

  2006cited by this paper
• Human Urotensin II Is a Novel Activator of NADPH Oxidase in Human Pulmonary Artery Smooth Muscle Cells

  2005cited by this paper
• Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension.

  2005cited by this paper
• Cardiac actions of central but not peripheral urotensin II are prevented by beta-adrenoceptor blockade.

  2005cited by this paper
• Human Urotensin II Accelerates Foam Cell Formation in Human Monocyte-Derived Macrophages

  2005cited by this paper
• Urotensin II: evidence for cardiac, hepatic and renal production.

  2005cited by this paper
• A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker.

  2005cited by this paper
• Nonpeptidic urotensin‐II receptor antagonists I: in vitro pharmacological characterization of SB‐706375

  2005cited by this paper
• Expression of urotensin-II in human coronary atherosclerosis.

  2005cited by this paper
• From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function.

  2004cited by this paper
• Mechanism of human urotensin II-induced contraction in rat aorta.

  2004cited by this paper
• Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases.

  2004cited by this paper
• Urotensin-II-Converting Enzyme Activity of Furin and Trypsin in Human Cells in Vitro

  2004cited by this paper
• Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord

  2004cited by this paper
• Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries.

  2004cited by this paper
• Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas.

  2004cited by this paper
• Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart.

  2004cited by this paper
• Differential levels of "urotensin-II-like" activity determined by radio-receptor and radioimmuno-assays.

  2004cited by this paper
• Central effects of native urotensin II on motor activity, ventilatory movements, and heart rate in the trout Oncorhynchus mykiss.

  2004cited by this paper
• Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta.

  2004cited by this paper
• Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure.

  2003cited by this paper
• Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects

  2003cited by this paper
• Direct Actions of Urotensin II on the Heart: Implications for Cardiac Fibrosis and Hypertrophy

  2003cited by this paper
• The neuromedin B receptor antagonist, BIM‐23127, is a potent antagonist at human and rat urotensin‐II receptors

  2003cited by this paper
• Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?

  2003cited by this paper
• Central cardiovascular action of urotensin II in spontaneously hypertensive rats.

  2003cited by this paper
• Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain.

  2003cited by this paper
• Detection of protease activities with the mass-spectrometry-assisted enzyme-screening (MES) system

  2003cited by this paper
• Increased plasma urotensin II levels in patients with diabetes mellitus.

  2003cited by this paper
• Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling.

  2003cited by this paper
• Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta

  2003cited by this paper

• Role of selective U-II receptor antagonists in modifying vascular function in intact and denuded aortic diabetic rats.

  2026cites this paper
• Elucidating the Pathogenic Mechanism of Spinal Muscular Atrophy Through the Investigation of UTS2.

  2025cites this paper
• Integrated analysis of blood microbiome and metabolites reveals key biomarkers and functional pathways in myocardial infarction

  2025cites this paper
• Urotensin-II receptor contributes to the pro-inflammatory TLR4/MyD88/NF-κB/iNOS/NO pathway-mediated cardiovascular response to systemic lipopolysaccharide challenge in a septic shock model in rats.

  2025cites this paper
• G-Protein-Coupled Receptors in Chronic Kidney Disease Induced by Hypertension and Diabetes

  2025cites this paper
• Enhanced negative modulation of urotensin II on cardiac function and [Ca2+]i regulation in a diabetic rat model: Insights into molecular and cellular mechanisms.

  2025cites this paper
• Expanding Structure-Activity Relationships of Human Urotensin II Peptide Analogues: A Proposed Key Role of the N-Terminal Region for Novel Urotensin II Receptor Modulators.

  2024cites this paper
• Elevated Urotensin-II and TGF-β Levels in COPD: Biomarkers of Fibrosis and Airway Remodeling in Smokers

  2024cites this paper
• The effects of the urotensin-II receptor antagonist palosuran treatment on the corpora cavernosa of streptozotocin-induced diabetic rats

  2024cites this paper
• Urotensin II promotes the proliferation and secretion of vascular endothelial growth factor in rat dermal papilla cells by activating the Wnt-β-catenin signaling pathway

  2023cites this paper
• Urotensin II can Induce Skeletal Muscle Atrophy Associated with Upregulating Ubiquitin–Proteasome System and Inhibiting the Differentiation of Satellite Cells in CRF Mice

  2023cites this paper
• Sex-biased gene regulation varies across human populations as a result of adaptive evolution

  2023cites this paper
• Activation of the urotensin-II receptor by remdesivir induces cardiomyocyte dysfunction

  2023cites this paper
• Interactome profiling of Crimean-Congo hemorrhagic fever virus glycoproteins

  2023cites this paper
• Urantide alleviates atherosclerosis-related liver and kidney injury via the Wnt/β-catenin signaling pathway in ApoE(−/−) mice

  2023cites this paper
• Globular adiponectin-mediated vascular remodeling by affecting the secretion of adventitial-derived tumor necrosis factor-α induced by urotensin II.

  2022cites this paper
• Activation of the urotensin-II receptor by anti-COVID-19 drug remdesivir induces cardiomyocyte dysfunction

  2022cites this paper
• Urotensin-II Prevents Cartilage Degeneration in a Monosodium Iodoacetate-Induced Rat Model of Osteoarthritis

  2022cites this paper
• Urotensin II level is elevated in inflammatory bowel disease patients

  2022cites this paper
• Urotensin II induces activation of NLRP3 and pyroptosis through calcineurin in cardiomyocytes.

  2021cites this paper
• Salidroside and isorhamnetin attenuate urotensin II-induced inflammatory response in vivo and in vitro: Involvement in regulating the RhoA/ROCK II pathway

  2021cites this paper
• Association of Serum Urotensin-II Levels with Insulin Resistance and Endothelin-I in Type-II Diabetes Mellitus Patients

  2021cites this paper
• Urotensin II levels in patients with inflammatory bowel disease

  2021cites this paper
• Urotensin II Induces Cardiac Fibrosis through the TGF-β/Smad Signaling Pathway during the Development of Cardiac Hypertrophy.

  2021cites this paper
• Urantide attenuates myocardial damage in atherosclerotic rats by regulating the MAPK signalling pathway.

  2020cites this paper
• Dynamic Changes in Plasma Urotensin II and Its Correlation With Plaque Stability

  2020cites this paper